ArticlePloS one2025
The impact of CwlM depletion on the susceptibility of Mycobacterium smegmatis to anti-tuberculosis drugs.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CRISPRi-mediated silencing of the ABC transporterFrontiers in microbiology · 2026Article
- Effects of CwlM, a peptidoglycan synthesis regulator, on beta-lactam tolerance and host-pathogen interactions.BMC microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CwlM, identified as an N-acetylmuramoyl-l-alanine amidase, plays crucial roles in the synthesis and remodeling of peptidoglycan in mycobacteria. This protein also appears to participate in both drug susceptibility and tolerance mechanisms within these organisms. In our study, we employed CRISPR interference (CRISPRi) to deplete CwlM in Mycobacterium smegmatis (M. smegmatis) and examined the resulting effects on the susceptibility of mycobacteria to first-line anti-tuberculosis drugs, including isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and ethambutol (EMB), as well as the β-lactams cefoxitin and imipenem. Our findings revealed that CwlM depletion increased the susceptibility of the bacterium to RIF, EMB, cefoxitin, and imipenem, while tolerance was heightened against INH and PZA. The enhanced antibiotic susceptibility can primarily be attributed to increased permeability of the bacterial cell wall. Conversely, the observed tolerance to INH might be ascribed to elevated expression of the amidase known as hydrazidase along with its LuxR-type regulator. Furthermore, several genes associated with peptidoglycan synthesis appeared to correlate with increased expression levels of either hydrazidase or its LuxR-type regulator. Collectively, these findings indicate that CwlM depletion significantly influences the susceptibility of M. smegmatis towards certain anti-tuberculosis drugs and may be implicated in drug susceptibility and tolerance mechanisms in M. smegmatis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.